Everest Medicines has introduced the business launch of VELSIPITY (etrasimod arginine tablets) in Mainland China, marking a big milestone within the therapy of ulcerative colitis (UC). The drug’s debut was highlighted by the issuance of the primary prescription at The First Affiliated Hospital of Sun Yat-sen University.
On its launch day, VELSIPITY was prescribed in eight tertiary hospitals throughout seven main cities, together with Guangzhou, Shanghai, and Beijing, offering speedy nationwide protection. The drug can be accessible by means of web hospital platforms, enhancing affected person entry.
VELSIPITY obtained approval from China’s National Medical Products Administration in February 2026, with the primary prescription issued only a month later, underscoring the robust scientific demand and Everest Medicines’ execution capabilities.
The launch comes as inflammatory bowel illness, significantly UC, is on the rise in China, pushed by way of life modifications and improved diagnostics. The affected person inhabitants is anticipated to develop considerably, with projections indicating the IBD therapy market may exceed RMB 10 billion by 2030.
VELSIPITY is a next-generation, extremely selective S1P receptor modulator, beneficial for reasonably to severely lively UC by main scientific tips. Clinical research have proven its potential for speedy onset of motion, long-lasting remission, and mucosal therapeutic, with a positive security profile.
In the ENLIGHT UC research, a Phase 3 scientific trial, VELSIPITY achieved a 48.1% scientific remission fee at week 40. The drug’s security and efficacy have been confirmed by means of real-world knowledge and long-term research, sustaining a secure security profile over 5 years.
Everest Medicines plans to leverage its commercialization expertise, gained from its nephrology product NEFECON, to drive VELSIPITY’s market development. NEFECON’s success has validated the corporate’s platform for progressive medication commercialization, which VELSIPITY is anticipated to duplicate.
With conventional UC remedies presenting limitations, VELSIPITY’s oral comfort and security profile place it as a promising different. Industry expectations recommend the drug may attain peak gross sales of RMB 5 billion, contributing considerably to Everest Medicines’ income development.
To improve accessibility and affordability, Everest Medicines goals to determine a multi-channel market entry framework and pursue inclusion in China’s National Reimbursement Drug List. This technique consists of affected person help packages and progressive fee options.